NEUP is Neuphoria Therapeutics Inc. (Healthcare) — a non-dividend-paying stock. Trading at $3.77. Market cap: $20M.
Stock snapshot
| Price | $3.77 |
| Market cap | $20M |
| Sector | Healthcare |
| Exchange | NGM |
| Pays dividend | No |
About NEUP
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Related non-dividend companies
Other non-dividend stocks investors research alongside NEUP. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is NEUP's current stock price?
NEUP (Neuphoria Therapeutics Inc.) is currently trading at $3.77.
Does NEUP pay a dividend?
NEUP (Neuphoria Therapeutics Inc.) does not currently pay a regular dividend.
Track NEUP in DiviDrip
Add NEUP to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search NEUP and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-07. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.